FasL has been suggested to mediate hepatic cell death in experimental models of hepatitis (Galle et al., 1995; Streetz et al., 2000) and blocking FasL signaling pathways indeed ameliorates liver disease to various degrees (Kondo et al., 1997; Ksontini et al., 1998). Here, FASLG is linked to hepatitis A virus infection.